Happy Ring vs Evie Ring (and EvieMED) in 2026

Happy Ring

The Happy Ring (from Happy Health Inc, Austin, Texas; CEO Dustin Freckleton, MD) is the FDA-cleared, service-gated archetype of the ring sub-cohort, and the sharpest verified-vs-claimed counterpoint to RingConn: the same finger-ring form factor and similar sleep-apnea capability claims, but a diametrically opposite verification posture. Its cleared sleep-apnea algorithm is the regulatory substance, with two dated FDA 510(k) clearances: K240236 (October 8, 2024) for retrospective remote monitoring of physiological parameters in adults at home or in healthcare facilities; and K242224 (June 18, 2025) for a Home Sleep Test that processes the ring's signals for clinician-interpreted diagnosis of sleep disorders such as obstructive sleep apnea and insomnia, ages 22+, under the direction of a trained healthcare provider (clinician-directed, not autonomous diagnosis).

It is not a standalone retail ring: it is sold only bundled into the clinician-reviewed, insurer-billed 'Happy Sleep' home-sleep-test service, so there is no published consumer price. Cap-flags: a 97% agreement with polysomnography is company-reported with no peer-reviewed citation; the 'brain biometrics' marketing is not substantiated by any named EEG hardware; and funding is a $60M Series A (August 2022, ARCH Venture Partners) with no later round surfaced, an early-stage state.

Evie Ring (and EvieMED)

Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued.

Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma.

DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).